First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rohrberg Kristoffer Staal, Melero Ignacio, F Sanmamed Miguel, Muñoz-Couselo Eva, Cervantes Andrés, Gambardella Valentina, Greillier Laurent, Garrido Pilar, Kim Hye Ryun, Lee Dae Ho, Italiano Antoine, Cassier Philippe Alexandre, Hiret Sandrine, Deva Sanjeev, Kim Tae Min, Blumenschein George R, Løvendahl Eefsen Rikke, Henick Brian S, Perro Mario, Umaña Pablo, Peixoto Antonio, Lauener Laura, Weber Patrick, Seeber Stefan, Klein Christian, Higgins Brian, Guidi Micol, Kraus Dominik, Mücke Merlind, Heichinger Christian, Tran Vu-Long, Schmid Daniela, Michielin Francesca, Liu Ting, McIntyre Christine, Kao Henry, Codarri Deak Laura, Markert Christoph, Moreno Victor
Аннотация
METHODS: Lomvastomig was characterized in cell cultures and preclinically in cancer mouse models. The phase 1, open-label, multicenter clinical study of lomvastomig included a dose-escalation part in patients with advanced and/or metastatic solid tumors and an expansion part with four tumor-specific cohorts, which enrolled checkpoint inhibitor (CPI)-experienced patients with melanoma and non-small-cell lung cancer (NSCLC) and CPI-naïve patients with SCLC and esophageal squamous cell carcinoma (ESCC). Primary and secondary objectives included safety/tolerability, maximum tolerated dose (MTD)/recommended dose for expansion (RDE), pharmacokinetics, drug receptor occupancy, and antitumor activity.
RESULTS: 39 and 95 patients were enrolled in the dose-escalation and expansion parts, respectively. Lomvastomig was well tolerated up to the highest tested dose of 2,100 mg every 2 weeks (Q2W). One dose-limiting toxicity was reported at 1,200 mg (grade 3 troponin T increase). No MTD was reached, and 2,100 mg Q2W was established as the RDE. Linear pharmacokinetics across the studied dose range suggested target saturation. Peripheral blood drug receptor occupancy on CD3+ and CD8+ was saturated at >90% throughout treatment for doses ≥70 mg. Objective responses were observed at 2,100 mg lomvastomig during dose-escalation (21%; n=19), and in the CPI-experienced melanoma (8%, n=38) and CPI-naïve ESCC (20%, n=15) expansion cohorts.
CONCLUSIONS: Lomvastomig had a tolerable and manageable safety profile at 2,100 mg Q2W. Clinical activity was limited in CPI-experienced patients with melanoma and NSCLC, while an encouraging signal was observed in CPI-naïve patients with ESCC.
TRIAL REGISTRATION NUMBER: NCT03708328 (registration date: 2018-10-09).